This segment focuses on the research, development, and clinical evaluation of oncolytic viral immunotherapies for the treatment of solid tumors. The core technology involves the use of modified vaccinia viruses, such as Olvi-Vec, to selectively infect and destroy cancer cells while stimulating an immune response. Research and development activities include preclinical studies, clinical trials, and manufacturing process development. The primary therapeutic areas are ovarian cancer and non-small cell lung cancer, with potential expansion into other solid tumor types. The patient impact is significant, as these therapies aim to provide new treatment options for aggressive and difficult-to-treat cancers. Market positioning is based on the innovative approach to cancer treatment, offering a targeted and immune-mediated mechanism of action. Future opportunities include expanding the pipeline with additional product candidates and exploring combination therapies. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations with other biotechnology companies and research institutions are essential for advancing the development and commercialization of these therapies.

This segment is dedicated to the development of V2ACT Immunotherapy, a therapeutic approach for treating pancreatic cancer. The research and development activities include preclinical studies, clinical trials, and manufacturing process development. The technology platform utilizes a proprietary approach to target and eliminate pancreatic cancer cells. The therapeutic area is specifically focused on pancreatic cancer, a disease with high unmet medical needs. The patient impact is aimed at improving survival rates and quality of life for patients with pancreatic cancer. Market positioning is based on providing a novel treatment option for a difficult-to-treat cancer. Future opportunities include expanding the clinical trials and exploring combination therapies. Regulatory and clinical aspects involve obtaining FDA approval and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations with other biotechnology companies and research institutions are essential for advancing the development and commercialization of this therapy.

This segment focuses on the development of V-VET1, a clinical-stage animal health product candidate. The research and development activities include preclinical studies, clinical trials, and manufacturing process development. The technology platform utilizes a proprietary approach to target and treat animal health conditions. The therapeutic area is focused on animal health, with the goal of improving the health and well-being of animals. The patient impact is aimed at improving the health and welfare of animals. Market positioning is based on providing a novel treatment option for animal health conditions. Future opportunities include expanding the clinical trials and exploring additional animal health applications. Regulatory and clinical aspects involve obtaining regulatory approvals and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations with animal health companies and research institutions are essential for advancing the development and commercialization of this product.